These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37084865)

  • 1. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
    Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
    Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse Collaborative Cross mice.
    Nagumalli SK; Willett RA; de Conti A; Tryndyak VP; Avigan MI; da Costa GG; Beland FA; Rusyn I; Pogribny IP
    J Nutr Biochem; 2022 Nov; 109():109108. PubMed ID: 35858665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis.
    Li H; Xu QY; Xie Y; Luo JJ; Cao HX; Pan Q
    Ann Hepatol; 2021; 24():100316. PubMed ID: 33515803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.
    Israelsen M; Kim M; Suvitaival T; Madsen BS; Hansen CD; Torp N; Trost K; Thiele M; Hansen T; Legido-Quigley C; Krag A;
    JHEP Rep; 2021 Oct; 3(5):100325. PubMed ID: 34401690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype.
    Erickson ML; Haus JM; Malin SK; Flask CA; McCullough AJ; Kirwan JP
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1197-1204. PubMed ID: 31371265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study.
    Li R; Kong D; Ye Z; Zong G; Hu K; Xu W; Fang P; Zhang L; Zhou Y; Zhang K; Xue Y
    Front Endocrinol (Lausanne); 2023; 14():1127134. PubMed ID: 36875464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study.
    Mann JP; Jenkins B; Furse S; Snowden SG; Alisi A; Draijer LG; Karnebeek K; Kelly DA; Koot BG; Mosca A; Salvestrini C; van Mourik I; Vreugdenhil A; Zilbauer M; Koulman A;
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):734-741. PubMed ID: 35185113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load.
    Gambino R; Bugianesi E; Rosso C; Mezzabotta L; Pinach S; Alemanno N; Saba F; Cassader M
    Int J Mol Sci; 2016 Mar; 17(4):479. PubMed ID: 27043543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
    J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approach using [
    Ustsinau U; Ehret V; Fürnsinn C; Scherer T; Helbich TH; Hacker M; Krššák M; Philippe C
    Clin Nutr; 2023 Oct; 42(10):1839-1848. PubMed ID: 37625314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cafeteria Diet and High-Fructose Rodent Models of NAFLD Differ in the Metabolism of Important PUFA and Palmitoleic Acid without Additional Influence of Sex.
    Mašek T; Barišić J; Micek V; Starčević K
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33143061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defects in High Density Lipoprotein metabolism and hepatic steatosis in mice with liver-specific ablation of Hepatocyte Nuclear Factor 4A.
    Thymiakou E; Othman A; Hornemann T; Kardassis D
    Metabolism; 2020 Sep; 110():154307. PubMed ID: 32622843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
    Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
    J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals.
    Saponaro C; Sabatini S; Gaggini M; Carli F; Rosso C; Positano V; Armandi A; Caviglia GP; Faletti R; Bugianesi E; Gastaldelli A
    Liver Int; 2022 Nov; 42(11):2418-2427. PubMed ID: 35900229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.